for Derp 1 and Derp 2, respectively. There was a significant negative correlation between exposure to . The correlation between Der p 2 and percent predicted FEV z just failed to reach a significant level but showed a clear trend (r = -0.35, p = 0.068). Conclusions: Clinical activity and severity of asthma (measured by the level of BHR, PEFR variability, and percent predicted FEV1) in mite-sensitive patients is related to exposure to mite allergens in the dust reservoir, with levels in bed being an important indicator that correlated with disease activity. (J Allergy Clin Immunol 1996;98:64-72.) 
in carpets and bedding during infancy is associated with increased prevalence of positive skin test results and increased levels of specific IgE to mites by the age of 5 years? Furthermore, in an infant cohort prospectively followed up from birth, Der p 1 levels of greater than 10 lxg/gm of dust measured in infancy were associated with 4.8-fold relative risk of developing asthma at the age of 11 years. 4 Studies from Papua, New Guinea, and other communities newly exposed to mites suggest that increased exposure to mite allergens is followed by increased prevalence of asthma. 5 Mite-sensitive asthma is less common at altitudes with low humidity and very few mites. 6, 7 There is a quantitative relationship between cumulative exposure to mite allergens and initial sensitization. 8 The development of asthma can be considered to consist of several distinct but probably related processes. First, exposure of the genetically predisposed individual to a critical level of allergen may result in sensitization, then further exposure of the sensitized individual leads to the development of airway inflammation and bronchial hyperresponsiveness (BHR). 9 This study investigated the relationship between ongoing mite allergen exposure and asthma severity. Prevalence rates are one way of measuring the magnitude and dimension of a particular disease. Severity and clinical activity also provide an important measure of the impact of the disease on patients' lives, the health care system, and the amount of medical care that an individual patient requires. In the case of asthma, several studies have suggested that these features may be related to allergen exposure. 1°42 This study investigated the relationship between exposure to the major house dust mite allergens (Dermatophagoides spp.
Group 1 and Group 2) and the severity and clinical activity of asthma as defined by the objective parameters of BHR, peak expiratory flow rate (PEFR) variability, and pulmonary function testing.
METHODS Subjects
For screening and entry into the study, patients were recruited from asthma registers in two large family practitioner surgeries. Subjects were selected by using a random one-in-four sample. A total of 200 patients was screened. Patients with a confirmed diagnosis of asthma were eligible to enter the study if they met the following criteria: (1) nonsmoking adults between the ages of 16 and 60 years; (2) receiving treatment with short-acting bronchodilators alone or in combination with inhaled steroids, long-acting 132-agonists , sodium cromoglycate, and/or nedocromil sodium; (3) no changes in asthma medication in the previous 3 months; (4) free of respiratory tract infection within the past 4 weeks. Before entry, each subject received a full explanation of the study and signed a consent form. The study protocol was approved by the ethics committees of Halton Borough and University Hospitals of South Manchester. Subjects were requested to withhold all bronchodilator medication for 6 hours (short-acting) or 24 hours (long-acting) before each study visit. Other asthma treatment was continued throughout the study. Each participant underwent the following procedures: (1) skin prick testing with common inhalant allergens (D. pteronyssinus, cat, mixed grasses, and trees; E. Merck Ltd., Alton, U.K.) (wheal diameter at least 3 mm greater than negative control considered a positive response); (2) bronchial provocation testing with methacholine to measure BHR; (3) pulmonary function testing on up to 3 separate occasions over the period of 4 weeks (individual measurements being at least 1 week apart); (4) recording of PEFR values at 2-hour intervals during waking hours for a total of 1 calendar month; (5) home visits for questionnaires and collection of domestic dust samples within 2 weeks of bronchial provocation test; (6) recording of symptom scores and bronchodilator use once daily (in the evening) throughout the study period on a diary card; and (7) airborne sampling in homes of patients with positive skin test responses to house dust mites.
Bronchial challenge and pulmonary function testing
Subjects underwent a methacholine bronchial challenge with Yan's technique. 13 Baseline pulmonary function was recorded on a dry bellows spirometer (Vitalograph, Buckinghamshire, U.K.) as the best of three efforts, with the two highest being within 5 % of one another. Subjects with a baseline FEV 1 of less than 50% of the predicted value were excluded from further study. Three inhalations of normal saline solution were then administered, and a postsaline FEV1 was measured after 1 minute. 
Symptom scores and bronchodilator use
Subjects were asked to record the presence, frequency, and severity of wheeze, breathlessness, and cough and the number of puffs of bronchodilators used. Daily aggregate symptom scores were averaged over a 4-week period. The scores were positively skewed and included many zero values. For this reason, the aggregate symptom scores were square root-transformed for analysis.
Dust sample collection, extraction, and allergen assay
Dust samples were collected by using a Medivac dust sampler (Medivac Plc., Wilmslow, U.K.) with an airflow rate of 45 L/see through a 355 Ixm diameter mesh screen on a 5 ~m vinyl filter (Plastok Associates Ltd., Wirral, U.K.), thus enabling collection of fine dust samples. Bedding (pillows and quilt) and a 1 m 2 area of bedroom carpet and mattress were vacuumed for 2 minutes. Dust samples were stored at 4 ° C until extracted. Each sample was weighed, and 100 mg of fine dust was extracted by rotation for 2 hours at room temperature with 2 ml of borate-buffered saline with 0.1% Tween-20, pH 8.0, and then centrifuged for 20 minutes at 2500 rpm at 4 ° C.
Supernatants were stored at -20 ° C for future analysis of allergen content. In addition, airborne samples were collected from the homes of 32 subjects with positive skin test responses to mites. Samples were taken overnight (8 hours) with a Casella AFC 123 personal sampler (2 L/min; Casella Ltd., London, U.K.) attached to the pillow. Filters were extracted in 1 ml of 1% bovine serum albumin in phosphate-buffered saline-Tween-20 overnight, filtered (0.2 ~m; Whatman Inc., Fairfield, N.J.) and stored at -20 ° C for future analysis of allergen content. Der p 1 and Der p 2 were measured with a two-site monoclonal antibody-based ELISA. t6, t7 Dust samples with Der p 1 and Der p 2 levels below the lower limit of detection of the assays were assigned a value of 100 ng/gm for further analysis, corresponding to the lower limit of detection of the assays.
Statistical analysis
Der p 1, Der p 2, dose-response ratio (DRR), and amplitude percent mean data were found to follow a log-normal distribution; the results are thus reported as geometric means (GMs) and 95% confidence limits (eL). The relationships between different variables were investigated by using linear regression. Differences in the level of exposure to mite allergen between the groups were investigated by using Student's t test. Statistical significance was set at a conventional 5% level.
RESULTS Demography
Fifty-three patients fulfilled the inclusion criteria and agreed to take part in the study (17 men and 36 women; mean age, 40.5 years). Those subjects not wishing to take part did not differ in either sex or age. Two subjects had infective exacerbations of their asthma during the course of the study, and their results were excluded from the analysis of asthma severity. Of the 51 subjects who successfully completed the study, three had a baseline FEV1 of less than 50% predicted for age and gender on 3 separate occasions (each with >15% reversibility) and therefore did not undergo bronchial challenge testing. Of the 48 participants who underwent methacholine challenge, 16 (33%) had PD20 greater than 12.25 ixmol methacholine. Methacholine nonreactors were assigned a value of 12.25 txmol for further analysis. The results of bronchial challenge testing were further expressed as DRR because a DRR value can be calculated for all subjects, however small their response to the challenge agent. Forty-eight satisfactorily completed PEFR records were analyzed, with an average of 23.7 days with at least four PEFR readings. The measures of disease activity in the studied group of 51 patients were as follows: PD20, GM = 2.63 (95% CL = 1.71-4.06) ~mol methacholine; amplitude percent mean PEFR, GM = 10.48% (95% CL = 9.16-11.99); percent predicted FEV1, mean = 88.74% (95% CL 82.94-94.53).
Thirty-nine of 53 patients who were enrolled in the study (73.6%) had a positive skin test response to at least one of the allergens tested; 32 (60.4%) had a positive response to mites. Twenty-five sub- jects had positive skin test responses to three or more allergens, eight had positive responses to two allergens, and six had positive responses to one allergen only.
House dust mite allergen exposure
Mean Der p 1 concentrations in house dust samples from the homes of 53 subjects who were enrolled in the study were 3.6, 1.2, and 4.4 ~g/gm in mattresses, bedroom carpets, and bedding, respectively. Although there was a highly significant correlation between Der p 1 in the mattresses and bedding (r = 0.68, p < 0.001), occasionally high levels of Der p 1 were found in bedding with low mattress levels and vice versa. There was an excellent correlation between Der p 1 and Der p 2 values (Fig. 2) in all of the analyzed samples, with the GM levels of allergens being 2.54 Ixg/gm (95% CL, 1.79-3.6) and 1.34 ~g/gm (95% CL, 0.97-1.84) for Der p 1 and Der p 2, respectively, with a Der p 1 to Der p 2 ratio of 1.89:1.
Airborne sampling
To investigate the possibility that airborne allergen exposure was more relevant than the allergen concentration in reservoir dust, we used personal samplers to measure airborne exposure to Der p 1 and Der p 2 in mite-sensitive subjects. Der p 1 and Der p 2 were undetectable in 30 of 32 (93.75%) airborne samples and barely detectable in two (<4 ng/ml; mean sample volume, 0.95 m3).
Allergen exposure and disease activity
Thirty-two subjects (13 men; mean age, 39 years) had positive skin test responses to mites. Of these, two experienced infective exacerbations of their asthma; one patient was a cat owner sensitized to both mites and cats and exposed to high levels of Fel d 1 (793 Ixg/gm in the bedding dust and 38 ng/m 3 in the airborne sample collected overnight). The test results for these three patients were therefore excluded, because both viral infection and sensitization and exposure to high levels of cat allergen would be important confounding factors, thus leaving 29 patients eligible for the analysis.
All 29 subjects had pulmonary function testing on up to 3 separate occasions. Two patients had a baseline FEV 1 of less than 50% of predicted value and therefore did not undergo bronchial challenge. The remaining 27 patients successfully completed bronchoprovocation testing (21 methacholine reactors). Two patients receiving treatment with a long-acting [32-agonist were excluded from the analysis of PEFR variability. The remaining 27 participants returned satisfactory PEFR diaries. The measures of disease activity in mite-sensitive subjects who successfully completed at least one part of the study (bronchial challenge, pulmonary function testing, or PEFR diaries) were: PD20, GM = 1.73 txmol methacholine (95% CL = 0.90-3.44); amplitude percent mean PEFR, GM = 11.13% (95% CL = 9.29-13.34); and percent predicted FEV1, mean = 86.24% (95% CL = 77.76-94.72); 21 subjects with negative skin test responses to mites did not differ significantly with respect to age, gender, or indices of disease activity.
There was a significant negative correlation between PD20 and Der p 1 level in mattress dust (log-transformed data: r = -0.46,p < 0.025). The association was strengthened when the highest level of Der p 1 in bed (mattress or bedding) was used as the index of personal exposure. The correlation between Der p 2 and percent predicted FEV~ just failed to reach a significant level but showed a clear trend (1-= -0.35, p = 0.068).
The correlation between the measures of disease activity and Der p 1 concentration in bedroom carpets was not significant (PDz0 , r = 0.01; DRR, r = 0.05; amplitude percent mean PEFR, r = 0.07; percent predicted FEV1, r = 0.30).
Reported symptoms and bronchodilator use correlated with neither the objective measures of asthma severity (BHR, PEFR variability, and pulmonary function;p > 0.1) nor the exposure to mite allergens in mite-sensitive patients.
In the group of patients with negative skin test responses to mites, no correlation was found between allergen exposure and BHR, amplitude percent mean PEFR, and percent predicted FEV 1 (p > 0.5).
DISCUSSION
BHR is a characteristic feature of most patients with asthma and can be objectively defined and measured by methacholine (or histamine) bronchoprovocation. The frequency of asthma symptoms and medication use correlates with the severity of BHR, and a number of factors can contribute to BHR and trigger asthma attacks. 18,19 Among these, exposure to indoor allergens, particularly those of house dust mites, can play an important role in both primary sensitization and later development of asthma. 2°
The level of BHR is arguably the best indirect indicator of severity of the underlying inflamma- tory process, which is a key feature of asthmatic airways. 21 Therefore the degree of BHR may indirectly reflect the severity of the disease process in asthma. If allergens play a role in the maintenance of airway inflammation, then a quantitative rela-tionship between the levels of exposure and BHR would be predicted. A study on exposure to mite allergen and pediatric hospital admissions has shown that most children admitted to the hospital because of exacerbation of asthma were both sensitized and exposed to mite allergen and also suggested that continued exposure to higher concentrations of mite allergen may be associated with the risk for readmission. 22 The results of this study support this suggestion, because in the group of patients with mite-sensitive asthma, those with demonstrable BHR were exposed to significantly higher levels of both group 1 and group 2 allergens than those without demonstrable BHR. The proportion of patients with PD20 greater than 12.25 ~mol methacholine is comparable to that of previous studies examining airway responsiveness to methacholine and histamine in patients with mild to moderate asthma, 18 because a smaller proportion of subjects without previous experience of forced expiratory maneuvers will have a PD20 that can be estimated. 23 Expressing the results as DRR enabled us to calculate the level of reduction in pulmonary function per unit of methacholine, and it is noteworthy that all methacholine nonreactors showed some level of decline in FEV 1 after the last dose of methacholine. Furthermore, the diagnosis of asthma in all participants was established by their family practitioner on the basis of reversibility after administration of bronchodilators or PEFR variability over a period of 2 weeks. We therefore believe that our sample is representative for the population of patients with asthma diagnosed and followed up in family practice. Thus a high level of allergen exposure is not only associated with the risk of exacerbation but also with increased BHR in patients with stable asthma treated outside the hospital setting.
Allergen exposure has been related to disease severity. In one of the first studies relating dust mites to asthma, visits to the hospital by patients with mite-sensitive asthma correlated with mite growth curves in their homes. 24 After a controlled or seasonal exposure to allergens, sensitized subjects experience an increase in BHR. 25, 26 Exposure to Alternaria allergen has been shown to be a risk factor for sudden respiratory arrest in patients with asthma. 27 When patients with mite-sensitive asthma move to a higher altitude or the mite-free environment of a hospital, their asthma improves. 28,29 House dust mite avoidance in the home is associated with symptomatic improvement and reduction in BHR and medication use? ° However, showing the direct relationship between allergen exposure and disease activity has always been difficult because of a number of possible confounding factors. Patients with asthma are often sensitized and exposed to more than one allergen. In our group, 30 patients had positive skin test responses to grass pollens, 29 to cats, and 16 to tree pollens. To avoid potential confounding by pollen, we designed the timing of the study to coincide with the end of the grass and tree pollen seasons (August to September). During the study period, the pollen counts obtained from the local pollen station remained very low and were unlikely to have influenced the results. Furthermore, individual plots of PEFR variability against grass and tree pollens in pollen-sensitive subjects showed no association (because of very low pollen counts). An effort was made to identify cat-sensitive cat owners, because exposure to cat allergen in this group of patients would be a major confounding factor. Only one subject was identified in this group and was unable to undergo bronchial challenge because of consistently low FEV 1 (<50%). Mean household exposure to cat allergen Fel d 1 in patients with positive skin test responses to both mites and cats was 1.3 ~g/gm of fine dust, the levels that are usually found in homes without a cat. 31 It is unlikely that exposure to cat allergen at these levels was a significant confounding factor in the analysis of mite allergen exposure-response relationship in asthma activity. Another important factor that can influence the level of BHR is viral infection? 2 By doing the study in the late summer, we missed the main season of viral respiratory tract infections, and therefore only two patients dropped out of the study because of respiratory tract infections. Subjects were asked to keep daily records of respiratory symptoms and bronchodilator use by rating the severity of each of three symptoms (wheeze, cough, and shortness of breath) on a visual analog scale from "none" to "worst ever" (10 cm lines) and to record the number of puffs of bronchodilator medication used. Neither reported symptoms nor bronchodilator use correlated with objective measures of asthma severity. This may be because there is considerable variability among individual perception of asthma severity and use of visual analog scales. Symptom scores and medication use are therefore more appropriate to longitudinal studies.
Theoretically, measurement of airborne allergen should be more representative of exposure than the levels in reservoir dusty There is still considerable debate about whether the level of mite allergen in settled dust from allergen reservoirs or VOLUME 98, NUMBER 1 the level in ambient air is a better index of exposure. 34 We failed to detect airborne mite allergens (Der p 1 or Der p 2) in all but two samples. This confirms that airborne sampling with current techniques has serious limitations as a routine method for the assessment of house dust mite allergen exposureY In our laboratory we are able to detect airborne mite allergens only after vigorous disturbance (e.g., vacuuming without a bag and filter).
The results of reservoir sampling were therefore used, and like Sporik et al., 4 who reported the highest Der p 1 level from different parts of the house, we considered exposure to be the highest concentration from samples collected in beds. The appropriate model to relate exposure information to dose, and this relationship to response, is not known. 8 We therefore decided to use a similar model of dose-response assessment, which has already been used in the analysis of exposure to mite allergen and the risk of allergic sensitization. 8 A linear relationship in exposure-response was assumed. 8 We have previously reported the absence of seasonal variation in Der p 1 level in the area, 35 making a single exposure measurement an appropriate measure of dose. Our results suggest that in mite-sensitive patients, the level of exposure to mite allergens has a major influence on severity and clinical activity of asthma. A similar correlation was seen for three measures of disease severity (BHR, PEFR variability, and pulmonary function) in subjects with positive skin test responses to mites, but no relationship was seen in those who had negative skin test responses. These results are in agreement with recent observations by Marks et al. 36 that Der p 1 concentration in beds correlates with the severity of BHR and asthma symptoms. Van der Heide et al. 37 have recently suggested that even small changes in exposure to mite allergens are associated with changes in airway responsiveness. The results of this study support this suggestion and question whether even relatively modest reduction in exposure could be of some benefit to the patient. However, if the assumption of a linear dose-response relationship is correct, a "no effect" level for exposure to mite allergens would not be able to be identified. (This threshold is known as the No Observed Adverse Effect Level. 3a) This would imply that there is no threshold concentration that could be generally applicable to every individual and below which no adverse effect on airway responsiveness or variability in pulmonary function would occur. There is probably considerable variability among individuals in the magnitude of response to the same levels of allergen exposure. Thus in a group of individuals with similar levels of IgE antibodies, some will experience symptoms only if they are exposed to high levels of allergens, whereas others require very low exposure to maintain symptoms; that is, the level of exposure necessary to induce and maintain airway inflammation, BHR, and symptoms varies over a wide range. 39 In conclusion, in patients with mite-sensitive asthma there is a dose-response relationship between the level of exposure to Group 1 and Group 2 house dust mite allergen and disease severity and clinical activity (as measured by level of BHR, PEFR variability, and pulmonary function testing).
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